NCT02837900View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of a Second Course of TPX-100 in Subjects Who Previously Received TPX-100 for Patellar Osteoarthritis Involving Both Knees

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Knee Osteoarthritis
Interventions
DRUG

TPX-100 200 mg 4 times weekly for 4 weeks

Ea. subject will received active TPX-100 200mg in the Left knee

DRUG

TPX-100 200 mg 4 times weekly for 4 weeks

TPX-100 100mg Right

Sponsors

Lead Sponsor

OrthoTrophix, Inc
All Listed Sponsors
lead

OrthoTrophix, Inc

INDUSTRY

NCT02837900 - A Study Evaluating the Safety and Efficacy of a Second Course of TPX-100 in Subjects Who Previously Received TPX-100 for Patellar Osteoarthritis Involving Both Knees | Biotech Hunter | Biotech Hunter